We work with a number of national and international research groups which all help to inform and accelerate our research in Nottingham.

• Hepatitis C Virus (HCV) Group co-ordinates the world’s largest HCV cohort (n=11,000), has £8.5M in active grants and leads the discovery of potent, broadly neutralising human monoclonal antibodies, now patented and in trial.
• Clostridia Research Group, underpinned by our £14.3M BBSRC/EPSRC Centre, is a world-class discovery unit in clostridial genetics, pathogenesis and synthetic biology with four recent filed patents.
• Helicobacter Group is an international leader in Hp genetics, virulence, immunity and treatment targets whose work underpins modern Hp virulence testing.
• UK-leading GI Epidemiology Group provides expert methodological support, and the Nottingham Clinical Trials Unit provides support for early patient-based translational study.
• Stem Cell Biology Group, with its specific stem cell based disease models; FRAME Alternatives Laboratory with its state-of-the-art cell biology facility (£1M) with expertise in culturing primary human cells; and the UK top-ranked School of Pharmacy, will translate GI and liver drug discovery/formulation programmes.
• We have strong links with the MRC/ARUK Centre (£2M) for Musculoskeletal Ageing Research resulting in internationally leading in in-vivo human, whole body physiological investigations within School of Nutritional Sciences, which underpin the development of new treatments for disorders of gastrointestinal and liver physiology and metabolism.